Key Highlights

  • Cellectis shares closed down 41% at $1.83.
  • The company announced a strategic pivot toward in vivo gene-editing programs.
  • Focus shifts to .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.
  • Cellectis is discontinuing clinical work on lasme-cel and eti-cel to stretch its cash runway into the second half of 2028.

Cellectis S.A. (NASDAQ: CLLS) shares closed down 41% at $1.83 after the company announced a strategic pivot toward in vivo gene-editing programs, focusing resources on .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.

What Happened

Initial Phase 1 readouts for the two programs are expected in the second half of 2027 and first half of 2028, respectively, while the company is discontinuing clinical work on lasme-cel and eti-cel to stretch its operational cash runway into the second half of 2028.

Market Reaction

Shares fell sharply as investors responded to the discontinuation of two existing clinical-stage programs, even as the company redirected focus and Capital toward its newer in vivo gene-editing pipeline.

Outlook

Initial Phase 1 readouts for .HEAL-101, expected in the second half of 2027, and .HEAL-201, expected in the first half of 2028, represent the next major disclosed milestones for Cellectis's newly prioritized pipeline.